Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Repare Therapeutics stock | $30.65

Learn how to easily invest in Repare Therapeutics stock.

Repare Therapeutics Inc is a biotechnology business based in the US. Repare Therapeutics shares (RPTX) are listed on the NASDAQ and all prices are listed in US Dollars. Repare Therapeutics employs 117 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Repare Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RPTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Repare Therapeutics stock price (NASDAQ: RPTX)

Use our graph to track the performance of RPTX stocks over time.

Repare Therapeutics shares at a glance

Information last updated 2021-09-17.
Latest market close$30.65
52-week range$21.76 - $46.44
50-day moving average $33.34
200-day moving average $32.27
Wall St. target price$47.63
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.08

Buy Repare Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
Get two free stocks valued between $3.00 and $300 with a deposit to any new account.
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Repare Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Repare Therapeutics price performance over time

Historical closes compared with the close of $30.65 from 2021-09-16

1 week (2021-09-10) -4.49%
1 month (2021-08-18) -8.75%
3 months (2021-06-18) -9.91%
6 months (2021-03-18) 7.09%
1 year (2020-09-18) -7.09%
2 years (2019-09-14) N/A
3 years (2018-09-14) N/A
5 years (2016-09-14) N/A

Repare Therapeutics financials

Revenue TTM $580,000
Gross profit TTM $-37,750,000
Return on assets TTM -14.13%
Return on equity TTM -27.47%
Profit margin 0%
Book value $6.60
Market capitalisation $1.2 billion

TTM: trailing 12 months

Shorting Repare Therapeutics shares

There are currently 903,011 Repare Therapeutics shares held short by investors – that's known as Repare Therapeutics's "short interest". This figure is 7.1% down from 972,376 last month.

There are a few different ways that this level of interest in shorting Repare Therapeutics shares can be evaluated.

Repare Therapeutics's "short interest ratio" (SIR)

Repare Therapeutics's "short interest ratio" (SIR) is the quantity of Repare Therapeutics shares currently shorted divided by the average quantity of Repare Therapeutics shares traded daily (recently around 86827.980769231). Repare Therapeutics's SIR currently stands at 10.4. In other words for every 100,000 Repare Therapeutics shares traded daily on the market, roughly 10400 shares are currently held short.

However Repare Therapeutics's short interest can also be evaluated against the total number of Repare Therapeutics shares, or, against the total number of tradable Repare Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Repare Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Repare Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0518% of the tradable shares (for every 100,000 tradable Repare Therapeutics shares, roughly 52 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Repare Therapeutics.

Find out more about how you can short Repare Therapeutics stock.

Repare Therapeutics share dividends

We're not expecting Repare Therapeutics to pay a dividend over the next 12 months.

Repare Therapeutics overview

Repare Therapeutics Inc. , a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small-molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, a proprietary drug discovery program for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

Frequently asked questions

What percentage of Repare Therapeutics is owned by insiders or institutions?
Currently 1.358% of Repare Therapeutics shares are held by insiders and 79.279% by institutions.
How many people work for Repare Therapeutics?
Latest data suggests 117 work at Repare Therapeutics.
When does the fiscal year end for Repare Therapeutics?
Repare Therapeutics's fiscal year ends in December.
Where is Repare Therapeutics based?
Repare Therapeutics's address is: 7210 Frederick-Banting, Montreal, QC, Canada, H4S 2A1
What is Repare Therapeutics's ISIN number?
Repare Therapeutics's international securities identification number is: US7602731025

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site